The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Molecular Epidemiology of Hepatitis B Virus

  • Kao, Jia-Horng (Department of Internal Medicine, Graduate Institute of Clinical Medicine, Hepatitis Research Center)
  • Published : 2011.09.01
⟨ Previous Next ⟩

Abstract

Although safe and effective vaccines for hepatitis B virus (HBV) have been available for nearly three decades, this virus kills at least 600,000 people annually worldwide and remains the leading global cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Because the HBV reverse transcriptase lacks a proofreading function, many HBV genotypes, subgenotypes, mutants, and recombinants exist. At least 10 HBV genotypes (HBV-A through J) with distinct geographic distributions have been identified; by definition, their complete genomic sequences diverge by more than 8%. HBV genotype is increasingly becoming recognized as an important factor in the progression and clinical outcome of HBV-induced disease. Infections by HBV-C or -D are significantly more likely to lead to cirrhosis and hepatocellular carcinoma than are infections by HBV-A or -B. Additionally, the hepatitis B e antigen seroconversion response to standard or pegylated interferon is more favorable in patients with HBV-A or -B than in those with HBV-C or -D. However, therapeutic responses to nucleos(t)ide analogues are generally comparable among HBV genotypes. In conclusion, genotyping of HBV is useful in identifying chronic hepatitis B patients who are at increased risk of disease progression, thereby enabling physicians to optimize antiviral therapy for these patients.

Keywords

References

  1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002;2:395-403. https://doi.org/10.1016/S1473-3099(02)00315-8
  2. Kao JH, Chen PJ, Chen DS. Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv Cancer Res 2010;108:21-72.
  3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-352. https://doi.org/10.1016/j.jhep.2007.11.011
  4. Lau JY, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993;342:1335-1340.
  5. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002;17:643-650. https://doi.org/10.1046/j.1440-1746.2002.02737.x
  6. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res 2010;40:14-30. https://doi.org/10.1111/j.1872-034X.2009.00601.x
  7. Lin CL, Kao JH. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci 2008;15:137-145. https://doi.org/10.1007/s11373-007-9225-8
  8. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol 2011;26 Suppl 1:123-130. https://doi.org/10.1111/j.1440-1746.2010.06541.x
  9. Kao JH, Chen DS. HBV genotypes: epidemiology and implications regarding natural history. Curr Hepat Rep 2006;5:5-13. https://doi.org/10.1007/s11901-006-0017-9
  10. Datta S. An overview of molecular epidemiology of hepatitis B virus (HBV) in India. Virol J 2008;5:156. https://doi.org/10.1186/1743-422X-5-156
  11. Phung TB, Alestig E, Nguyen TL, Hannoun C, Lindh M. Genotype X/C recombinant (putative genotype I) of hepatitis B virus is rare in Hanoi, Vietnam: genotypes B4 and C1 predominate. J Med Virol 2010;82:1327-1333. https://doi.org/10.1002/jmv.21775
  12. Tatematsu K, Tanaka Y, Kurbanov F, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 2009;83:10538-10547. https://doi.org/10.1128/JVI.00462-09
  13. McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009;3:334-342. https://doi.org/10.1007/s12072-008-9112-z
  14. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1134-1143. https://doi.org/10.1093/jnci/djn243
  15. Chen JD, Liu CJ, Lee PH, et al. Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2004;2:64-71. https://doi.org/10.1016/S1542-3565(03)00293-3
  16. Lin CL, Chen JD, Liu CJ, et al. Clinicopathological differences between hepatitis B viral genotype B- and C-related resectable hepatocellular carcinoma. J Viral Hepat 2007;14:64-69.
  17. Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002;123:1848-1856. https://doi.org/10.1053/gast.2002.37041
  18. Livingston SE, Simonetti JP, McMahon BJ, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007;195:5-11. https://doi.org/10.1086/509894
  19. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010;28:2437-2444. https://doi.org/10.1200/JCO.2009.27.4456
  20. Sugiyama M, Tanaka Y, Kato T, et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006;44:915-924. https://doi.org/10.1002/hep.21345
  21. Liu CJ, Jeng YM, Chen CL, et al. Hepatitis B virus basal core promoter mutation and DNA load correlate with expression of hepatitis B core antigen in patients with chronic hepatitis B. J Infect Dis 2009;199:742-749. https://doi.org/10.1086/596655
  22. Chen RY, Bowden S, Desmond PV, Dean J, Locarnini SA. Effects of interferon alpha therapy on the catalytic domains of the polymerase gene and basal core promoter, precore and core regions of hepatitis B virus. J Gastroenterol Hepatol 2003;18:630-637. https://doi.org/10.1046/j.1440-1746.2003.03019.x
  23. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005;25:1097-1107. https://doi.org/10.1111/j.1478-3231.2005.01177.x
  24. Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 2008;13:613-624.
  25. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000;33:998-1002. https://doi.org/10.1016/S0168-8278(00)80135-X
  26. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005;54:1009-1013. https://doi.org/10.1136/gut.2004.060327
  27. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305. https://doi.org/10.1046/j.1365-2893.2003.00450.x
  28. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695. https://doi.org/10.1056/NEJMoa043470
  29. Zhao H, Kurbanov F, Wan MB, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007;44:541-548. https://doi.org/10.1086/511042
  30. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129. https://doi.org/10.1016/S0140-6736(05)17701-0
  31. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006;101:297-303. https://doi.org/10.1111/j.1572-0241.2006.00418.x
  32. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008;135:459-467. https://doi.org/10.1053/j.gastro.2008.05.031
  33. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009;136:2169-2179.e1-e4. https://doi.org/10.1053/j.gastro.2009.03.006
  34. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther 2009;14:1183-1188. https://doi.org/10.3851/IMP1458
  35. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008;13:211-220.
  36. Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol 2010;52:441-449. https://doi.org/10.1016/j.jhep.2009.12.014
  37. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-2009. https://doi.org/10.1053/j.gastro.2009.08.061
  38. Hsieh TH, Tseng TC, Liu CJ, et al. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C. Antivir Ther 2009;14:1157-1163. https://doi.org/10.3851/IMP1454
  39. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455. https://doi.org/10.1056/NEJMoa0802878
  40. Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 2007;1:415-430. https://doi.org/10.1007/s12072-007-9033-2
  41. Kao JH. Appropriate use of interferon for treatment of chronic hepatitis B. Hepatol Res 2007;37(s1):S47-S54. https://doi.org/10.1111/j.1872-034X.2007.00105.x
  42. Cooksley WG. Do we need to determine viral genotype in treating chronic hepatitis B? J Viral Hepat 2010;17:601-610.

Cited by

  1. Hepatitis B Precore Protein: Pathogenic Potential and Therapeutic Promise vol.53, pp.5, 2011, https://doi.org/10.3349/ymj.2012.53.5.875
  2. Epidemiology and Molecular Characterization of Hepatitis B Virus Infection in Isolated Villages in the Western Brazilian Amazon vol.87, pp.4, 2011, https://doi.org/10.4269/ajtmh.2012.12-0083
  3. Correlation between Hepatitis B Virus Genotypes and Clinical Outcomes vol.65, pp.6, 2012, https://doi.org/10.7883/yoken.65.476
  4. Study on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method vol.13, pp.None, 2013, https://doi.org/10.1186/1472-6882-13-239
  5. Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B vol.10, pp.1, 2013, https://doi.org/10.1186/1743-422x-10-214
  6. HBeAg‐positive chronic hepatitis B: why do I treat my patients with pegylated interferon? vol.34, pp.suppl1, 2011, https://doi.org/10.1111/liv.12400
  7. Epidemiology of hepatitis B virus infection among recyclable waste collectors in central Brazil vol.47, pp.1, 2011, https://doi.org/10.1590/0037-8682-0177-2013
  8. Lack of Association Between Transforming Growth Factor Beta 1 -509C/T and +915G/C Polymorphisms and Chronic Hepatitis B in Iranian Patients vol.14, pp.3, 2011, https://doi.org/10.5812/hepatmon.13100
  9. Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages vol.30, pp.1, 2015, https://doi.org/10.1111/jgh.12654
  10. Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures vol.87, pp.6, 2015, https://doi.org/10.1002/jmv.24153
  11. Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity vol.31, pp.10, 2011, https://doi.org/10.1111/jgh.13338
  12. A G-quadruplex motif in an envelope gene promoter regulates transcription and virion secretion in HBV genotype B vol.45, pp.19, 2011, https://doi.org/10.1093/nar/gkx823
  13. CHRONIC HEPATITIS B vol.56, pp.4, 2011, https://doi.org/10.5633/amm.2017.0408
  14. Seroepidemiology of Hepatitis Viruses and Hepatitis B Genotypes of Female Marriage Immigrants in Korea vol.59, pp.9, 2018, https://doi.org/10.3349/ymj.2018.59.9.1072
  15. Performance evaluation of cobas HBV real-time PCR assay on Roche cobas 4800 System in comparison with COBAS AmpliPrep/COBAS TaqMan HBV Test vol.56, pp.7, 2011, https://doi.org/10.1515/cclm-2017-1133
  16. Performance evaluation of cobas HBV real-time PCR assay on Roche cobas 4800 System in comparison with COBAS AmpliPrep/COBAS TaqMan HBV Test vol.56, pp.7, 2011, https://doi.org/10.1515/cclm-2017-1133
  17. Host Transcription Factors in Hepatitis B Virus RNA Synthesis vol.12, pp.2, 2011, https://doi.org/10.3390/v12020160
  18. Biological features of hepatitis B virus strains associated with fulminant hepatitis vol.15, pp.7, 2011, https://doi.org/10.2217/fvl-2020-0011
  19. Quantitative analysis of the splice variants expressed by the major hepatitis B virus genotypes vol.7, pp.1, 2021, https://doi.org/10.1099/mgen.0.000492
  20. Molecular Epidemiology of Hepatitis B Virus (HBV) Genotypes Prevalent in KP vol.17, pp.4, 2011, https://doi.org/10.13005/bbra/2877
  21. Molecular identification of genotypes of Hepatitis B virus in Borno State, Nigeria vol.15, pp.2, 2011, https://doi.org/10.5897/ajmr2019.9270